Exploration of Cardiology

Table 2. Frequency of demographic and therapeutic factors of poor prognosis primary malignant cardiac tumors.

Variable	Category	Count	Percent
Age group	Middle (45–64 years)	250	68.31
Age group	Elderly (≥ 65 years)	85	23.22
Age group	Youth (< 45 years)	31	8.47
Sex	Male	195	53.28
Sex	Female	171	46.72
Race	White	213	58.20
Race	Other	107	29.23
Race	Black	46	12.57
Surgery	None	161	43.99
Surgery	Simple/partial surgical removal of the primary site	57	15.57
Surgery	Excisional biopsy	50	13.66
Surgery	Local tumor excision, NOS	44	12.02
Surgery	Debulking surgery	20	5.46
Surgery	Enucleation	13	3.55
Surgery	Local tumor excision, partial/total removal, laser excision	7	1.91
Surgery	Radical surgery	7	1.91
Surgery	Surgery, NOS	4	1.09
Surgery	Unknown/death	2	0.55
Surgery	Polypectomy	1	0.27
Radiation	None	302	82.51
Radiation	Radiation	64	17.49
Chemotherapy	Yes	188	51.37
Chemotherapy	None	178	48.63
Income	Above (≥ $75,000)	270	73.77
Income	Below (< $75,000)	96	26.23
Rural-urban	Urban	326	89.07
Rural-urban	Rural	40	10.93
Prognosis group	I (< 50% survival at 5 years)	366	100.00
Cancer subtype	Soft tissue	294	80.33
Cancer subtype	Other	45	12.30
Cancer subtype	Heme	24	6.56
Cancer subtype	Embryonal	3	0.82
Metastasis—bone	No	191	52.19
Metastasis—bone	N/A	147	40.16
Metastasis—bone	Yes	28	7.65
Metastasis—brain	No	206	56.28
Metastasis—brain	N/A	150	40.98
Metastasis—brain	Yes	10	2.73
Metastasis—liver	No	198	54.10
Metastasis—liver	N/A	149	40.71
Metastasis—liver	Yes	19	5.19
Metastasis—lung	No	173	47.27
Metastasis—lung	N/A	147	40.16
Metastasis—lung	Yes	46	12.57
Tumor size (per mm)	Median	65
Tumor size (per mm)	IQR	35

Return to article view

N/A: not applicable; NOS: not otherwise specified; IQR: interquartile range.

Supplementary materials

The supplementary table for this article is available at: https://www.explorationpub.com/uploads/Article/file/1012107_sup_1.xlsx.

Declarations

Acknowledgments

The authors would like to thank the University of Missouri-Kansas City School of Medicine for its academic support and scholarly resources.

Author contributions

RM: Conceptualization, Investigation, Writing—original draft, Writing—review & editing, Project administration, Supervision. ZM: Investigation, Data curation, Writing—original draft, Writing—review & editing. SK: Data curation, Formal analysis, Resources, Validation, Writing—original draft, Writing—review & editing. JJ: Writing—original draft, Writing—review & editing. TA: Supervision, Project administration. All authors read and approved the submitted version.

Conflicts of interest

The authors declare no conflicts of interest.

Ethical approval

This study utilized de-identified data from the publicly available Surveillance, Epidemiology, and End Results (SEER) Program database. As the dataset contains no identifiable patient information and involves no direct interaction with human participants, this study was considered exempt from Institutional Review Board review and the requirement for informed consent was waived, consistent with the ethical principles outlined in the Declaration of Helsinki.

Consent to participate

This study utilized de-identified data from the publicly available Surveillance, Epidemiology, and End Results (SEER) Program database. As the dataset contains no identifiable patient information and involves no direct interaction with human participants, the informed consent was waived, consistent with the ethical principles outlined in the Declaration of Helsinki.

Consent to publication

Informed consent was waived because this study used publicly available, de-identified data from the Surveillance, Epidemiology, and End Results (SEER) Program database, which contains anonymized cancer registry information collected for public health surveillance. No identifiable patient information was accessed.

Availability of data and materials

Data is publicly available and submitted with the manuscript as supplemental materials. The data analyzed in this study were obtained from the SEER database. Requests for access to these datasets should be directed to https://seer.cancer.gov/data/access.html.

Funding

This study was not supported by any sponsor or funder.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Garcia Brás P, Branco LM, Galrinho A, Timóteo AT, Branco Mano T, Ferreira V, et al. Malignant Primary and Metastatic Cardiac Tumors: A Single-Center 27-Year Case Review. Oncology. 2023;101:292–302. [DOI] [PubMed]

Oliveira GH, Al-Kindi SG, Hoimes C, Park SJ. Characteristics and Survival of Malignant Cardiac Tumors: A 40-Year Analysis of > 500 Patients. Circulation. 2015;132:2395–402. [DOI] [PubMed]

Chen X, Chen Y, Xiao F, Liu M, Gu Z, Li Y, et al. Survival and analysis of prognostic factors for primary malignant cardiac tumors based on the SEER database. J Cancer Res Clin Oncol. 2023;149:15687–96. [DOI] [PubMed] [PMC]

Maraj S, Pressman GS, Figueredo VM. Primary cardiac tumors. Int J Cardiol. 2009;133:152–6. [DOI] [PubMed]

Perchinsky MJ, Lichtenstein SV, Tyers GF. Primary cardiac tumors: forty years’ experience with 71 patients. Cancer. 1997;79:1809–15. [DOI] [PubMed]

Hudzik B, Miszalski-Jamka K, Glowacki J, Lekston A, Gierlotka M, Zembala M, et al. Malignant tumors of the heart. Cancer Epidemiol. 2015;39:665–72. [DOI] [PubMed]

Wang W, Kang L, Zhang J, Li H, Cao T, He S. Age and treatment disparities in survival of primary malignant cardiac tumors: an analysis of over 40 years and 500 patients. J Thorac Dis. 2023;15:4434–44. [DOI] [PubMed] [PMC]

SEER Incidence Data, 1975–2023 [Internet]. NIH and SEER; [cited 2025 Aug 23]. Available from: https://seer.cancer.gov/data/index.html

Javed Z, Haisum Maqsood M, Yahya T, Amin Z, Acquah I, Valero-Elizondo J, et al. Race, Racism, and Cardiovascular Health: Applying a Social Determinants of Health Framework to Racial/Ethnic Disparities in Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2022;15:e007917. [DOI] [PubMed]

10.

Gordon MJ, Danilova O, Spurgeon S, Danilov AV. Cardiac non-Hodgkin’s lymphoma: clinical characteristics and trends in survival. Eur J Haematol. 2016;97:445–52. [DOI] [PubMed]

11.

Sun D, Wu Y, Liu Y, Yang J. Primary cardiac myxofibrosarcoma: case report, literature review and pooled analysis. BMC Cancer. 2018;18:512. [DOI] [PubMed] [PMC]

12.

Amano J, Nakayama J, Yoshimura Y, Ikeda U. Clinical classification of cardiovascular tumors and tumor-like lesions, and its incidences. Gen Thorac Cardiovasc Surg. 2013;61:435–47. [DOI] [PubMed] [PMC]

13.

Maleszewski JJ, Basso C, Bois MC, Glass C, Klarich KW, Leduc C, et al. The 2021 WHO Classification of Tumors of the Heart. J Thorac Oncol. 2022;17:510–8. [DOI] [PubMed]

14.

Heaton JN, Dhaduk N, Okoh AK, Dang-Ho KP, Tayal R, Salemi A, et al. Characteristics, management, and outcomes among admissions for primary cardiac tumors: Results from the National Inpatient Sample. J Card Surg. 2021;36:3586–92. [DOI] [PubMed]

15.

Cao J, Tan Z, Yang E, Ji Q, Fang M, Liu J. Clinical characteristics and treatment outcomes of primary cardiac sarcomas: a retrospective analysis. Cardiooncology. 2025;11:109. [DOI] [PubMed] [PMC]

16.

Ramlawi B, Leja MJ, Abu Saleh WK, Al Jabbari O, Benjamin R, Ravi V, et al. Surgical Treatment of Primary Cardiac Sarcomas: Review of a Single-Institution Experience. Ann Thorac Surg. 2016;101:698–702. [DOI] [PubMed]

17.

Blackmon SH, Reardon MJ. Surgical treatment of primary cardiac sarcomas. Tex Heart Inst J. 2009;36:451–2. [PubMed] [PMC]

18.

Carras S, Berger F, Chalabreysse L, Callet-Bauchut E, Cordier JF, Salles G, et al. Primary cardiac lymphoma: diagnosis, treatment and outcome in a modern series. Hematol Oncol. 2017;35:510–9. [DOI] [PubMed]

19.

Grebenc ML, Rosado de Christenson ML, Burke AP, Green CE, Galvin JR. Primary cardiac and pericardial neoplasms: radiologic-pathologic correlation. Radiographics. 2000;20:1073–103. [DOI] [PubMed]